SEATTLE, WA -- September 19, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Drug Discovery, will be introducing a number of new technologies in lab automation, cellular screening and reagents at the Society for Biomolecular Screening (SBS) 12th Annual Conference and Exhibition in Seattle, Washington, September 17-21 2006, booth #329.

For the first time, PerkinElmer will showcase its new JANUS™ Cellular Workstation, a fully automated liquid handling platform designed for cellular assays. The JANUS Cellular Workstation combines cutting-edge PerkinElmer technologies including reagent chemistries, detection systems, and liquid handling for walk-away automation of medium and high throughput applications. This total system solution approach provides proven, pre-defined application templates and system scheduling with documented results and application guides allowing laboratories to rapidly and easily generate results.

The Company will also unveil the PerkinElmer CS Autoplex Workstation, which uses the latest in automated multiplex technology for assay set-up, sample processing and analysis for high content xMAP technology. All of which delivers reproducibility equivalent to the manual processing of cellular assays. This end-to-end solution utilizes the JANUS™ Automated Workstation and the PerkinElmer CS 1000 Analyzer for complete assay automation, from sample preparation to results generation.

PerkinElmer will also unveil the FlexDrop Plus, the newest version of the popular FlexDrop dispensing system, which has been enhanced to be easier to use and minimize reagents consumption. FlexDrop PLUS continues to deliver superior dispense precision at nanoliter volumes.

In addition, PerkinElmer will introduce advances to its LANCE® assay product line. LANCE® Ultra is a new improved homogenous TRF platform for TR-FRET assays enabling higher sensitivity, speed, and productivity in PerkinElmer’s high-throughput screening assay platform.

“Advances in lab automation, multiplex and reagent technologies, are driving new levels of data collection, and resulting in more accurate, relevant and reproducible leads for new drug candidates,” says Dr. Richard Eglen, vice president and general manager, Discovery and Research Reagents for PerkinElmer’s Life & Analytical Sciences business. “Research is being conducted on an increasingly complex scale, and these technologies will be critical to automating and managing experimental workflows in today’s modern drug discovery labs.”

On Sunday, September 17, PerkinElmer hosted a Technology Workshop: “Functional Assay Solutions for Drug Discovery”, with presentations by PerkinElmer scientists, customers, and key drug discovery opinion leaders. The Workshop is a forum for examining the various approaches to assay development and screening, and will take place from 8:30 am - 4:30 pm in Room 612 at the Washington State Convention and Trade Center.

PerkinElmer will host a Tutorial on Monday, September 18 from 8:00 am-8:45 am in room 618. The tutorial, “Improved Productivity & Versatility with Screening Solutions from PerkinElmer,” will feature presentations on PerkinElmer’s LumiLux™ Cellular Screening Platform and the JANUS™ Scaleable and Modular Automated Platforms.

PerkinElmer will showcase the following products at booth #329 throughout the conference:

• LANCE® Technology — new, enhanced homogenous TR-FRET assay platform for HTS and uHTS.
• AlphaScreen SureFire™ Cellular Kinase Assays — sensitive, homogenous cellular kinase screening assays.
• AlphaScreen® PhosphoSensor Kit — homogenous luminescence platform for antibody-free kinase activity measurements using even large substrates.
• LumiLux™ Cellular Screening Platform — breakthrough luminescence uHTS cellular screening system for both adherent and suspension cells.
• JANUS™ Cellular Workstation — a new fully automated liquid handling platform designed for cellular assays.
• CS Autoplex Workstation — for complete preparation and detection of multiplexed assays.
• FlexDrop™ Plus — a newly enhanced version of the popular dispensing system
• Microplates — high quality microplates for all your biomolecular assays

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (2) risks related to our failure to introduce new products in a timely manner; (3) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (4) a delay in resolution of the Company’s tax audits and an adverse determination with respect to the Company’s tax audits by the Internal Revenue Service or other taxing authorities; (5) cyclical downturns continuing to affect several of the industries into which we sell our products; (6) our ability to adjust our operations to address unexpected changes; (7) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (8) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (9) competition; (10) regulatory compliance; (11) regulatory changes; (12) our failure to obtain and enforce intellectual property protection; (13) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (14) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.